**FOI Ref: 6284**

**Category(ies): Clinical - Drugs**

**Subject: Dermatological Conditions**

**Date Received: 10/03/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am analysing the usage of new biologic medications for the treatment of dermatological conditions. I would greatly appreciate if you could answer the following question.  How many patients were treated in February 2022 (or latest available month) by the dermatology department with the following drugs:   * Abrocitinib (Cibinqo) * Baricitinib (Olumiant) * Bimekizumab (Bimzelx) * Brodalumab (Kyntheum) * Dupilumab (Dupixent) * Ixekizumab (Taltz) * Risankizumab (Skyrizi) * Guselkumab (Tremfya) * Secukinumab (Cosentyx) * Tildrakizumab (Ilumetri) * Tralokinumab (Adtralza) * Upadacitinib (Rinvoq) * Ustekinumab (Stelara) | |  |  | | --- | --- | | Abrocitinib (Cibinqo) | 0 | | Baricitinib (Olumiant) | 1 | | Bimekizumab (Bimzelx) | 0 | | Brodalumab (Kyntheum) | 2 | | Dupilumab (Dupixent) | 12 | | Ixekizumab (Taltz) | 0 | | Risankizumab (Skyrizi) | 0 | | Guselkumab (Tremfya) | 12 | | Secukinumab (Cosentyx) | 4 | | Tildrakizumab (Ilumetri) | 0 | | Tralokinumab (Adtralza) | 0 | | Upadacitinib (Rinvoq) | 0 | | Ustekinumab (Stelara) | 4 | |